Seqcureneo

We are on a mission to cure.

SeqCure Immunology was founded in 2016 by Karolinska scientists Robert Wallin, Ludvig Linton and Vidar Wendel-Hansen with a solution to bring curative T cell immunotherapy to all cancer patients - including those with advanced cancer who often cannot benefit from other treatment options.

In line with the views of Key Opinion Leaders, we are convinced that this type of individualized and specific therapeutic approach is necessary for curing cancer and that it will form the basis for cancer treatment in the future. We have assembled a team of experts within the fields of cancer immunology, cell therapy, process development, regulatory strategy and clinical- and business development in order to implement our plan to initiate clinical trials within two years from initial funding.

Our core team is presented below.

Vidar Wendel-Hansen, PhD
Chief Executive Officer
‍
Vidar has a PhD in tumor biology from the Karolinska Institute. After a few years in clinical practice, he embarked on a career within life science industry. He has extensive experience from management positions within pharmaceutical companies such as Novartis and Gilead Sciences, as well as from smaller biotech startups. Vidar has also worked as a clinical assessor at the Swedish Medical Products Agency. 

‍

Robert Wallin, PhD
Chief Scientific Officer

Ludvig Linton, PhD
Chief Operating Officer

Chief Executive Officer

Vidar Wendel-Hansen

Vidar has a PhD in tumor biology from the Karolinska Institute. After a few years in clinical practice, he embarked on a career within life science industry. He has extensive experience from management positions within pharmaceutical companies such as Novartis and Gilead Sciences, as well as from smaller biotech startups. Dr. Wendel-Hansen has also worked as a clinical assessor at the Swedish Medical Products Agency.

Chief Scientific Officer

Robert Wallin

Robert is an Associate Professor of Immunology and has broad experience in the field of cancer immunotherapy, the development of which he has closely followed since 1993. Robert has leadership experience from the Karolinska Institute and from his role as Vice President Education at the Indonesian International Institute for Life Science (I3L) in Jakarta, Indonesia.‍

Chief Operating Officer

Ludvig Linton

Ludvig developed a deep interest in immunotherapy following his doctoral studies within the field of intestinal immunology at the Karolinska Institutet. He has since gained experience from project management, regulatory- and clinical development and science commercialization from various biotech startups.